Clinical Trial

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2023 (before its estimated December 18, 2025 completion). Its status may not reflect the trial's current state.
Summary
Phase I clinical trials are designed as open-label, dose-escalation and dose-expansion clinical studies, the main purpose of which is to explore the tolerability, safety, cytokinetic characteristics and RP2D and preliminary observation of the efficacy of the study drug in subjects with B7-H3-positive relapsed/refractory neuroblastoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-09-27; most recent amendment 2023-02-23.
Status change: Not Yet Recruiting → Recruiting 2023-02-23
Trial Details
NCT Number NCT05562024
Lead Sponsor PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborators: Tianjin Medical University Cancer Institute and Hospital, Shandong Cancer Hospital and Institute
Conditions B7-H3-positive Relapsed/ Refractory Neuroblastoma
Enrollment 24 participants
Start Date 2022-12-30
Primary Completion 2025-12-18 (estimated)
Study Completion 2039-02-18 (estimated)
Updated on ClinicalTrials.gov 2023-02-27